| Holding(s) in Company | 04-Dec-2025 | 15:00 | RNS |
| Block listing Interim Review | 01-Dec-2025 | 15:05 | RNS |
| Total Voting Rights | 01-Dec-2025 | 15:00 | RNS |
| Imfinzi approved in US for early gastric cancer | 26-Nov-2025 | 07:00 | RNS |
| AstraZeneca manufacturing investment in Maryland | 24-Nov-2025 | 07:00 | RNS |
| Koselugo (selumetinib) approved in the US | 20-Nov-2025 | 07:00 | RNS |
| Holding(s) in Company | 17-Nov-2025 | 15:00 | RNS |
| Director/PDMR Shareholding | 14-Nov-2025 | 11:00 | RNS |
| Director/PDMR Shareholding | 10-Nov-2025 | 15:00 | RNS |
| 9M and Q3 2025 results | 06-Nov-2025 | 07:00 | RNS |
| Result of General Meeting | 03-Nov-2025 | 16:00 | RNS |
| Total Voting Rights | 03-Nov-2025 | 15:00 | RNS |
| Director Declaration | 28-Oct-2025 | 07:05 | RNS |
| Koselugo (selumetinib) approved in the EU | 28-Oct-2025 | 07:00 | RNS |
| Tezspire Approved in EU for CRSwNP | 22-Oct-2025 | 07:00 | RNS |
| Currency | UK Pounds |
| Share Price | 13,592.00p |
| Change Today | 78.00p |
| % Change | 0.58 % |
| 52 Week High | 14,148.00p |
| 52 Week Low | 9,667.00p |
| Volume | 1,461,235 |
| Shares Issued | 1,550.73m |
| Market Cap | £210,775m |
| RiskGrade | 123 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 10 |
| Buy | 13 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

| Latest | Previous | |
|---|---|---|
| 1st Interim | 2nd Interim | |
| Ex-Div | 07-Aug-25 | 20-Feb-25 |
| Paid | 08-Sep-25 | 24-Mar-25 |
| Amount | 103.00¢ | 210.00¢ |
| Time | Volume / Share Price |
| 16:27 | 0 @ 13,578.00p |
| 16:11 | 0 @ 13,552.00p |
| 16:11 | 0 @ 13,552.00p |
| 16:09 | 0 @ 13,554.00p |
| 16:09 | 0 @ 13,554.00p |
You are here: research